Overview

CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria

Status:
Completed

Trial end date:
2017-05-08

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effects of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) compared to Meropenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis caused by β-lactamase producing gram-negative bacteria

Phase:

Phase 3

Details

Lead Sponsor:

Venus Remedies Limited

Treatments:

Anti-Infective Agents
Ceftriaxone
Edetic Acid
Meropenem
Pentetic Acid
Sulbactam
Thienamycins